Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 29
Filter
1.
Ann Hematol ; 90(12): 1457-65, 2011 Dec.
Article in English | MEDLINE | ID: mdl-21503644

ABSTRACT

This study was conducted to evaluate the safety and efficacy of platelet concentrates (PC) after photochemical treatment (PCT) with the INTERCEPT Blood System™ and transfused in routine use in a population of patients suffering from a variety of hematological diseases. This was an observational, single-arm, open-label study of pooled buffy-coat PC (n=298) or apheresis PC (n=262) treated with INTERCEPT™ and transfused to 51 thrombocytopenic hematology patients. PCT replaced CMV screening and gamma irradiation, and made optional bacterial testing obsolete. The primary study endpoint was the incidence of acute transfusion reactions (ATR). Secondary endpoints included bleeding assessment, platelet count increments, and adverse events (AE). For the 553 transfusions, a total of 55 AE were observed regardless of relationship to platelet transfusion. Ten AE associated with nine transfusions met the criteria for ATR (1.6%). All ATRs were grade 1. Twelve serious AE were reported in 10 patients, none was related to platelet transfusion. Mean 24-h CI and CCI were 10.9 × 10(9) and 6.6 × 10(3)/L, respectively. No bleeding complications were attributable to the INTERCEPT-treated PC. This study confirms safety and efficacy of pathogen inactivated PC for support of thrombocytopenia and demonstrated that INTERCEPT technology can easily be implemented in routine operations.


Subject(s)
Blood Platelets/microbiology , Platelet Transfusion/methods , Thrombocytopenia/therapy , Adult , Aged , Blood Platelets/radiation effects , Female , Humans , Male , Middle Aged , Platelet Transfusion/adverse effects , Plateletpheresis/methods , Treatment Outcome , Young Adult
2.
Transfusion ; 48(6): 1122-32, 2008 Jun.
Article in English | MEDLINE | ID: mdl-18298595

ABSTRACT

BACKGROUND: An in vitro erythropoiesis assay is a powerful tool for investigating red blood cell (RBC) development and diseases of the erythroid lineage. Most assays, however, failed in either proliferation or terminal differentiation. Here two liquid cultures (LCs) for in vitro generation of RBCs from peripheral blood CD34+ cells were compared. STUDY DESIGN AND METHODS: Granulocyte-colony-stimulating factor-mobilized CD34+ cells were cultured for 16 days in a two-phase LC (2P-LC; Days 1-8, stem cell factor [SCF], erythropoietin [EPO], insulinlike growth factor [IGF]-1, and steroids; Days 9-16, EPO and insulin) and for 21 days in a three-phase LC (3P-LC; Days 1-7, SCF, thrombopoetin, and Flt3-ligand; Days 8-14, SCF, EPO, and IGF-1; Days 15-21, EPO and IGF-1). Maturation was analyzed by flow cytometry (CD36, CD71, glycophorin A [GPA]) and microscopy. RESULTS: In the 2P-LC, cell numbers increased from 0.5 x 10(6) to 25.7 x 10(6) +/- 15.1 x 10(6) cells per mL. More than 95 percent were GPA+ and showed morphologic characteristics of normoblasts (52 +/- 15%) and enucleated reticulocytes (43 +/- 18%). In the 3P-LC, a higher overall proliferation to 55.7 x 10(6) +/- 37.7 x 10(6) cells per mL was achieved (p < 0.05). This was also accompanied by a high degree of normoblasts (36 +/- 16%) and reticulocytes (48 +/- 24%). The amount of GPA+ cells was slightly lower (88.4 +/- 16.4%), associated with a significantly higher contamination by nonerythroid cells (15.8 +/- 19.3% vs. 3.9 +/- 2.9%, p < 0.05). CONCLUSION: Both LCs were able to generate fully matured RBCs and represent powerful tools for fundamental research in erythroid development and diseases targeting the erythroid lineage. A slightly higher proliferation was achieved in the 3P-LC. This was associated with a limited homogeneity due to more nonerythroid cells, however. Therefore the 2P-LC is favored, also saving additional culture days and growth factors.


Subject(s)
Antigens, CD34/metabolism , Cell Culture Techniques/methods , Cell Differentiation , Erythrocytes/cytology , Leukocytes/cytology , Leukocytes/metabolism , Biomarkers , Cell Membrane/metabolism , Cell Proliferation , Coculture Techniques , Colony-Forming Units Assay , Hematopoietic Stem Cells/cytology , Humans
3.
Eur J Immunol ; 37(6): 1702-9, 2007 Jun.
Article in English | MEDLINE | ID: mdl-17506029

ABSTRACT

Systemic lupus erythematosus (SLE), an autoimmune disease characterized by chronic nephritis, arthritis and dermatitis, and the presence of antinuclear autoantibodies, is associated with complement factor deficiencies in the classical activation pathway. In addition, IFN-alpha seems to be a key cytokine in SLE as an activated IFN-alpha system is regularly observed in patients with SLE. Here, we demonstrate that in lupus-susceptible, complement C4-deficient mice the lack of complement results in elevated intravascular levels of apoptotic DNA. The apoptotic DNA is targeted to the splenic marginal zone where it accumulates and induces IFN-alpha. As such, we present here a unifying hypothesis for the induction of SLE that incorporates the role of complement deficiency and elevated levels of IFN-alpha.


Subject(s)
Apoptosis/immunology , Complement C4/genetics , DNA/metabolism , Interferon-alpha/genetics , Lupus Erythematosus, Systemic/immunology , Animals , Antibodies, Antinuclear/immunology , Antibodies, Antinuclear/metabolism , Antibodies, Antinuclear/pharmacology , Antibodies, Monoclonal/immunology , Antibodies, Monoclonal/metabolism , Antibodies, Monoclonal/pharmacology , Antigen-Antibody Complex/analysis , Antigen-Antibody Complex/immunology , Apoptosis/genetics , CD11b Antigen/analysis , Complement C4/deficiency , DNA/immunology , DNA/pharmacology , Flow Cytometry , Gene Expression/drug effects , Immunoglobulin M/immunology , Immunoglobulin M/metabolism , Immunoglobulin M/pharmacology , In Situ Nick-End Labeling , Interferon-alpha/metabolism , Interferon-gamma/genetics , Interferon-gamma/metabolism , Leukocyte Common Antigens/analysis , Lupus Erythematosus, Systemic/genetics , Lupus Erythematosus, Systemic/metabolism , Mice , Mice, Inbred C57BL , Mice, Knockout , RNA, Messenger/genetics , RNA, Messenger/metabolism , Reverse Transcriptase Polymerase Chain Reaction , Spleen/cytology , Spleen/immunology , Spleen/metabolism
4.
Biol Reprod ; 76(4): 645-53, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17151351

ABSTRACT

Leukocyte recruitment to the pregnant mouse uterus is associated with highly regulated patterns of expression of vascular adhesion receptors. One striking observation is the localized expression of mucosal vascular addressin cell adhesion molecule (MADCAM1) and selectin, platelet (SELP, formerly P-selectin) by maternal vessels in the vascular zone (VZ) during the first half of pregnancy. From midgestation onwards, endothelial cells lining the maternal vessels of the VZ in addition express vascular cell adhesion molecule-1 (VCAM1). The predominant cell population within these vessels is monocyte-like cells. Granulocytes and low numbers of lymphocytes are also present. Murine fetal trophoblast cells are almost devoid of adhesion molecules, including SELP. In contrast, spontaneous abortions of allogeneic pregnancies are characterized by dramatic upregulation of SELP on maternal VZ vessels and on fetal trophoblast cells. Upregulation of SELP is associated with a dramatic influx of highly activated granulocytes, which infiltrate the vessels and tissue of the VZ and the trophoblast. The majority of the activated granulocytes within the trophoblast undergo nuclear fragmentation, which can be detected by TUNEL staining. To demonstrate that SELP is involved in the recruitment of granulocytes to the pregnant uterus, we undertook long-term in vivo inhibition studies using a monoclonal antibody to inhibit the contribution of SELP to leukocyte trafficking to the decidua. In addition, the pregnant uteri of syngeneic Selp(-/-) x Selp(-/-) mice were investigated and compared to the controls. Our results clearly demonstrate the importance of SELP for granulocyte access to the pregnant mouse uterus under physiological and pathological conditions.


Subject(s)
Abortion, Veterinary/pathology , Cell Movement/physiology , Granulocytes/cytology , P-Selectin/physiology , Pregnancy, Animal , Uterus/cytology , Uterus/pathology , Abortion, Veterinary/genetics , Animals , Embryo Loss/genetics , Embryo Loss/pathology , Female , Gene Expression Regulation , Male , Mice , Mice, Inbred BALB C , Mice, Inbred C57BL , Mice, Knockout , Models, Biological , P-Selectin/genetics , Pregnancy , Uterus/metabolism
5.
Immunology ; 120(2): 261-72, 2007 Feb.
Article in English | MEDLINE | ID: mdl-17137465

ABSTRACT

The relationship between immunostimulation of human B cells by cytosine-phosphate-guanosine (CpG) -containing oligonucleotides and their physical cellular uptake is of mechanistic interest and a prerequisite for rational improvements of the therapeutic potential of CpG-harbouring oligonucleotides. Here, a combinatorial approach was used to identify nucleotide sequence motifs that facilitate increased cellular uptake in mammalian cells. Oligonucleotides harbouring the selected hexanucleotide TCGTGT in cis show increased cellular uptake. This motif contains a CpG dinucleotide within a sequence context that shows a very strong CpG-specific stimulatory activity on human B cells. Here we describe the influence of concentration, length and sequence position of the unmethylated CpG dinucleotide on immunostimulation. A comparison between phosphorothioate-derivatives and unmodified TCGTGT-containing oligonucleotides strongly indicates a great CpG-specificity for the unmodified CpG-harbouring oligonucleotides but not for the phosphorothioate versions. This work describes a link between the physical cellular uptake of naked oligonucleotides harbouring the selected cellular uptake motif TCGTGT, its strong CpG-specific stimulation of human B cells and its relationship with the sequence context of CpG and its cellular uptake.


Subject(s)
Leukocytes, Mononuclear/immunology , Oligodeoxyribonucleotides/immunology , B-Lymphocytes/immunology , B-Lymphocytes/metabolism , Base Sequence , Cells, Cultured , Combinatorial Chemistry Techniques , CpG Islands/genetics , CpG Islands/immunology , DNA Mutational Analysis , Dose-Response Relationship, Immunologic , Gene Library , Humans , Leukocytes, Mononuclear/metabolism , Lymphocyte Activation/immunology , Molecular Sequence Data , Oligodeoxyribonucleotides/genetics , Oligodeoxyribonucleotides/pharmacokinetics , Tumor Cells, Cultured
6.
Transfusion ; 46(12): 2176-83, 2006 Dec.
Article in English | MEDLINE | ID: mdl-17176332

ABSTRACT

BACKGROUND: Usually, a predonation hemoglobin (Hb) measurement must precede blood donation. Hb values of a donor's previous donation might be used for selecting a subgroup in which predonation Hb measurements are unnecessary. STUDY DESIGN AND METHODS: Only donors with historical Hb values below 129 or 139 g per L for female and male donors, respectively, underwent venous Hb measurement before phlebotomy with an automated hematology analyzer. All other donor phlebotomies were collected without initial Hb testing. Hb values from diversion samples from 81,913 consecutive donors between May 2003 and November 2005 were subsequently analyzed as representing their present values. Donors were grouped according to interdonation intervals of less than 6, 6 to 11, 12 to 23, and 24 months or more. RESULTS: The arithmetic mean deviation between historical and present Hb values was between -0.3 and +1.8 g per L for each group (mean deviation, 5.2-6.7 g/L). Not testing selected donors spared 77.7 percent from a prephlebotomy Hb measurement and showed a specificity of 29 percent. Sensitivities for detection of donors below Hb limits (between 56% and 67% for the different subgroups) and donors with Hb values below 110 g per L (82%-88%) were at least comparable to capillary Hb screening. A total of 4.8 percent of donors were phlebotomized with values below 125 and 135 g per L, whereas only 0.016 percent of donors were bled despite Hb levels below 110 g per L. CONCLUSION: Selecting donors for a current Hb measurement based upon their last whole-blood predonation Hb value is a useful method, even after prolonged interdonation intervals.


Subject(s)
Blood Donors , Hemoglobins/analysis , Female , Humans , Male , Sensitivity and Specificity
7.
Int Immunol ; 16(12): 1685-90, 2004 Dec.
Article in English | MEDLINE | ID: mdl-15477230

ABSTRACT

Defects of early complement components (C1, C4 and C2) are associated with the development of systemic lupus erythematosus (SLE). The availability of complement knockout mice has increased our knowledge on the role of complement in the regulation of adaptive immunity. An impaired removal of apoptotic bodies, a disturbed clearance of IgG immune complexes (ICs) and an insufficient B-cell regulation via complement receptors CD21/CD35 have been discussed as explanations for the induction of autoimmunity; however, a unifying hypothesis for the loss of B-cell tolerance in the absence of C1 or C4 is still lacking. Using IgM-containing ICs, we observed a significant accumulation of antigen within the splenic marginal zone (MZ) of C4-deficient mice but not in C3-deficient or complement receptors CD21/CD35-deficient mice. The targeting of antigen toward the MZ restored adaptive immunity (antibody response and class switch) in C4-deficient animals. A new explanation for the association of SLE and complement C4 deficiency would be that in the absence of C4, natural antibodies (IgM type) localize more self-antigen toward the MZ so that the auto-antibody response is increased and autoimmune disease ensues. As such, an inadequate localization of self-antigens might be responsible for the annulment of peripheral B-cell tolerance in the absence of C4.


Subject(s)
Autoantibodies/biosynthesis , Autoantigens/immunology , Complement C4/deficiency , Immunoglobulin Class Switching , Immunoglobulin G/biosynthesis , Lupus Erythematosus, Systemic/immunology , Spleen/immunology , Animals , Antigen-Antibody Complex/immunology , Antigen-Antibody Complex/metabolism , Autoantigens/analysis , Autoimmunity , B-Lymphocytes/immunology , Complement C3/deficiency , Complement C3/genetics , Complement C4/genetics , Immunoglobulin G/genetics , Immunoglobulin G/immunology , Immunoglobulin M/biosynthesis , Immunoglobulin M/immunology , Lupus Erythematosus, Systemic/genetics , Mice , Mice, Knockout , Receptors, Complement 3b/immunology , Receptors, Complement 3d/immunology , Self Tolerance/immunology , Tissue Distribution
8.
J Hepatol ; 41(4): 667-72, 2004 Oct.
Article in English | MEDLINE | ID: mdl-15464249

ABSTRACT

BACKGROUND/AIMS: RNA editing controls the formation of hepatitis-delta-antigen-S and -L and therefore plays a central role in the hepatitis-delta-virus (HDV) life-cycle. Editing is catalyzed by the enzyme Adenosine-deaminase-acting-on-RNA1 (ADAR1) of which two different forms, ADAR1-L and ADAR1-S, exist. As ADAR1-L is induced by interferon (IFN)-alpha, we examined the influence of IFN-alpha-stimulation of host cells on HDV-RNA editing. METHODS: Editing was studied in Huh-7-cells transfected with HDV-RNA on days 7, 14, 21 and 28 after transfection. ADAR1-L mRNA was measured by RT-PCR. RESULTS: IFN-alpha-treatment led to a 5-fold higher expression of ADAR1-L and to an increase in editing from 14+/-2% (SD) in unstimulated controls to 27+/-4% (SD) on day 7 after transfection. Editing further increases over time to the same maximum level of 35% in IFN-alpha-treated as well as untreated cells. CONCLUSIONS: By IFN-alpha-stimulation both ADAR1-L expression and editing are increased in Huh-7-cells at day 7, and the maximum level of edited antigenomes is reached earlier with IFN-alpha-treatment as compared to untreated cells. Thus, ADAR1-L appears to be able to increase editing, but the HDV genome apparently has an intrinsic negative feed-back regulation mechanism that limits editing to roughly a third of the genomes.


Subject(s)
Antiviral Agents/pharmacology , Hepatitis D/virology , Hepatitis Delta Virus/genetics , Interferon-alpha/pharmacology , Liver/drug effects , Liver/virology , RNA Editing , Adenosine Deaminase/biosynthesis , Adenosine Deaminase/genetics , Cell Line, Tumor , DNA, Viral , Humans , Isoenzymes/biosynthesis , Isoenzymes/genetics , Liver/enzymology , RNA Editing/drug effects , RNA, Messenger/metabolism , RNA-Binding Proteins , Time Factors , Transfection
9.
Eur Cytokine Netw ; 15(2): 99-104, 2004.
Article in English | MEDLINE | ID: mdl-15319167

ABSTRACT

The peptide hormone prolactin (PRL) is produced by specialized cells in the anterior pituitary gland and in a number of sites outside the pituitary. Its biological actions consist of various roles in reproduction, lactation, and of a number of homeostatic biological activities that also include immune functions. Elevated serum PRL concentrations often correlate with abnormalities in immune responses. To determine the influence of PRL on human immune cells, human whole blood cultures were stimulated with lipopolysaccharide (LPS), supplemented with various concentrations of human recombinant PRL. We found that PRL, at concentrations achievable during pregnancy, anesthesia and medication, significantly amplified interleukin (IL)-12 and tumor necrosis factor-alpha (TNF-alpha) synthesis in LPS-stimulated cultures, in a dose-dependent manner. Conversely, synthesis of the anti-inflammatory cytokine IL-10 only increased significantly at very high concentrations of supplemented PRL. PRL alone was not able to induce any measurable secretion of TNF-alpha, IL-10, or IL-12 in non-stimulated, whole blood cultures. However, we demonstrated that PRL, by itself or in combination with LPS, causes an increase in the binding activity of the transcription factors nuclear factor-kappaB (NFkappaB) and interferon regulatory factor-1 (IRF-1), which are known to promote TNF-alpha and IL-12 secretion. These data suggest that PRL promotes pro-inflammatory immune responses via NFkappaB and IRF-1, which may affect pathophysiological processes in physiological hyperprolactinemic states.


Subject(s)
Blood Cells/immunology , Cytokines/biosynthesis , DNA-Binding Proteins/metabolism , Lipopolysaccharides/pharmacology , NF-kappa B/metabolism , Phosphoproteins/metabolism , Prolactin/physiology , Cells, Cultured , Dose-Response Relationship, Drug , Dose-Response Relationship, Immunologic , Humans , Hyperprolactinemia/immunology , Immunity/physiology , Inflammation/immunology , Interferon Regulatory Factor-1 , Lactation/physiology , Pituitary Gland, Anterior/metabolism , Prolactin/pharmacology , Reproduction/physiology , Signal Transduction/drug effects , Signal Transduction/immunology
10.
Transfusion ; 44(5): 758-63, 2004 May.
Article in English | MEDLINE | ID: mdl-15104659

ABSTRACT

BACKGROUND: CD34+ PBPCs for autologous transplantation purposes are collected by leukapheresis procedures on automated cell separators. In this study, the influence of different parameters on collection efficiency (CE) of the Amicus Crescendo cell separator (Baxter) was investigated. STUDY DESIGN AND METHODS: A total of 146 PBPC collections with Amicus cell separators were performed in 56 patients with either settings recommended by the manufacturer or modified settings to identify variables that have a significant and important impact on CE. RESULTS: By use of a standard setting with a cycle volume of 1400 mL, CE significantly decreases when patients' preapheresis peripheral blood WBC counts are between 25,000 and 35,000 per micro L. CE can be improved if cycle volume is reduced to 1000 mL. If WBC concentrations exceed 55,000 per micro L before apheresis, CE also significantly decreases despite of reduced cycle volume. Additionally, high flow rates greater than 60 mL per minute significantly reduce CE. CONCLUSION: Parameters influencing the outcome of CD34+ PBPC collections were identified, such as patients' WBC count, cycle volume, and whole blood flow rate. An optimized adjustment of these variables will further increase the CE of the device.


Subject(s)
Antigens, CD34/analysis , Hematopoietic Stem Cell Mobilization , Leukapheresis/instrumentation , Female , Humans , Leukocyte Count , Male
11.
World J Biol Psychiatry ; 5(1): 33-7, 2004 Jan.
Article in English | MEDLINE | ID: mdl-15048633

ABSTRACT

The existence of atypical lymphocytes with specific morphological characteristics in the peripheral blood of schizophrenic patients has been suggested in several reports over the last 40 years. In our study this observation was examined not only by using the formerly applied method of light microscopy for general cell distribution and lymphocyte morphology but also by applying flow cytometry, a well established immunological method for lymphocyte patterns such as lymphocyte subgroups and lymphocyte activity. In contrast to the previously published data, our results demonstrated no differences in cell distribution (lymphocytes, polymorphonuclear cells, eosinophil and basophil granulocytes, monocytes), lymphocyte morphology ("atypical lymphocytes" vs. "normal lymphocytes"), distribution of lymphocyte-subtypes (T-cells (CD3(+)), T-helper-cells (CD3(+)/CD4(+)), cytotoxic T-cells (CD3(+)/CD8(+)), B-cells (CD19(+)), NK-cells (CD3(-)/CD56(+))) or state of T-lymphocyte activity (CD25(+) or HLA-DR(+)-cells) in schizophrenic patients compared to healthy controls. We suggest that possible immunological alterations in schizophrenia do not correlate with morphological characteristics of lymphocytes observable by light microscopy or an altered state activity of T-lymphocytes examined by flow cytometric parameters. Further studies should concentrate on intracellular and functional aspects of the different lymphocyte subgroups.


Subject(s)
Antigens, CD/immunology , Schizophrenia/immunology , Adult , Aged , Antigens, CD/classification , Female , Flow Cytometry/methods , Humans , Male , Middle Aged
12.
Am J Transplant ; 4(3): 402-6, 2004 Mar.
Article in English | MEDLINE | ID: mdl-14961993

ABSTRACT

Recently, we demonstrated an association of the IL-6 promoter polymorphism at position -174 (G-->C) with kidney allograft survival whereby carriers of the -174GG genotype were identified as having superior graft survival. As two additional polymorphisms were discovered in the neighborhood at positions -572 (G-->C) and -597 (G-->A), respectively, and as functional studies revealed a cooperative impact of all three on the IL-6 gene transcription, we investigated whether there is a combined effect on kidney transplant outcome. We determined IL-6 promoter haplotypes -597 (G-->C)/-572 (G-->A)/-174 (G-->C)(-597/-572/-174haplotype) using a PCR system with sequence-specific primers in 158 patients after primary cadaveric kidney transplantation. We here show that the -597 and -174 polymorphism are in tight-linkage disequilibrium and that homozygous carriers of the GGG-597/-572/-174 haplotype (GGG/GGG genotype) have superior 3-year graft survival rates compared with the 8.0-fold increased risk of premature graft loss in all other patients. Interestingly, patients carrying the GGG/GCG genotype had the lowest allograft survival rate. Thus determination of the combined -597/-572/-174 genotype allows for further differentiation of -174GG patients into subgroups and consequently for a more accurate identification of patients at risk. Our results indicate that the three polymorphisms act in a cooperative fashion and we provide evidence for an exceptional clinical impact of the IL-6-597/-572/-174 genotype on the success of kidney transplantation.


Subject(s)
Graft Survival/genetics , Interleukin-6/genetics , Kidney Transplantation , Promoter Regions, Genetic , Humans , Polymorphism, Single Nucleotide
13.
Clin Chem ; 50(1): 141-51, 2004 Jan.
Article in English | MEDLINE | ID: mdl-14709642

ABSTRACT

BACKGROUND: To optimize immunosuppressive treatment in individual transplant patients, functional measurements of the effects of tacrolimus (FK 506) are of clinical importance. Previous investigations have demonstrated the occurrence of tacrolimus-resistant production of interleukin-2 (IL-2) in vitro, which may explain in part why rejection episodes are still a frequent problem despite attainment of therapeutic blood concentrations and HLA matching. However, an adequate surrogate marker to define the tacrolimus response in individual patients has not been established. METHODS: We investigated the immunosuppressive effects of tacrolimus on anti-CD3/anti-CD28 T-cell costimulation in a human whole-blood assay, analyzing T-cell proliferation, activation marker expression (CD25, CD69), IL-2 protein expression, and cytokine mRNA expression in vitro (n = 11 healthy individuals). We also quantified IL-2 mRNA expression in patients undergoing tacrolimus (n = 4) or cyclosporin A (CsA; n = 4) monotherapy before ex vivo living-donor kidney transplantation. RESULTS: T-cell proliferation; CD25, CD69, and IL-2 concentrations; and IL-4 mRNA were significantly decreased in vitro. In contrast, cytokine mRNA profiles revealed variable tacrolimus sensitivity. Whole-blood samples from 3 of 11 healthy individuals demonstrated marked suppression of IL-2 mRNA expression (>50%) when tacrolimus was administered in vitro. When CsA was added to whole-blood cultures, the influence on IL-2 mRNA expression was comparable to that of tacrolimus in 9 of 11 individuals. Two individuals responded conversely, indicating that differences in the in vitro response to tacrolimus and CsA among individuals may be attributable to potential heterogeneity in the involvement of the CD28 pathway. Kinetic profiles of IL-2 mRNA expression also revealed individually distinct degrees of calcineurin inhibitor sensitivity in patients undergoing tacrolimus or CsA monotherapy before living-donor kidney transplantation. CONCLUSIONS: Our results suggest an individual degree of calcineurin inhibitor sensitivity of activated whole-blood lymphocytes based on IL-2 mRNA expression. Our approach is potentially valuable for identifying transplant patients in whom IL-2 mRNA expression is unaffected or even enhanced after initiation of immunosuppressive therapy. Such individuals may be less sensitive to the immunosuppressive agent and therefore at increased risk of transplant rejection. Prospective studies are necessary to determine the correlation of IL-2 mRNA expression with the clinical risk of transplant rejection.


Subject(s)
Immunosuppressive Agents/pharmacology , Interleukin-2/biosynthesis , RNA, Messenger/biosynthesis , T-Lymphocytes/drug effects , Tacrolimus/pharmacology , Adult , Antigens, CD/biosynthesis , Antigens, Differentiation, T-Lymphocyte/biosynthesis , Cell Division/drug effects , Cyclosporine/therapeutic use , Flow Cytometry , Humans , In Vitro Techniques , Kidney Transplantation/immunology , Lectins, C-Type , Middle Aged , Receptors, Interleukin-2/biosynthesis , Reference Values , T-Lymphocytes/cytology , T-Lymphocytes/metabolism
14.
Eur J Nucl Med Mol Imaging ; 31(3): 403-7, 2004 Mar.
Article in English | MEDLINE | ID: mdl-14685783

ABSTRACT

The transfusion of allogenic, in vitro expanded natural killer cells (NKC) is a novel therapy option in oncology. To date, however, the biodistribution and kinetics of allogenic NKC have not been investigated. Therefore, in this study three patients with renal cell carcinoma received 3-7 x 10(8) NKC labelled with indium-111 oxine with a tenfold excess of unlabelled cells during NKC therapy. Whole-body scintigrams were obtained (0.5-144 h) in the anterior and posterior views. Scintigrams were analysed using a region of interest technique, and single-photon emission tomography (SPET) studies of the abdomen were performed. Results were compared to those obtained with polymerase chain reaction (PCR) of the peripheral blood (determination of foreign DNA, nested PCR, limit of detection 0.01%). Shortly after transfusion of NKC, more than 50% of the activity was accumulated in the lungs. We observed redistribution effects from lungs to liver, spleen and bone marrow. No significant loss of activity could be detected. In two of four large metastases, tracer accumulation could be proven by SPET. As confirmed by scintigrams and PCR, the fraction of circulating transfused cells was low at all times. Long-term activity retention might be caused either by survival of the allogenic cells, as confirmed by PCR (up to 3 days p.i.), or by phagocytosis of labelled cellular fragments. However, PCR data and uptake in metastases indicated long survival of a portion of allogenic NKC. Such long survival and low retention of the cells in the lung are requirements for an effective immunotherapeutic approach.


Subject(s)
Carcinoma, Renal Cell/diagnostic imaging , Carcinoma, Renal Cell/therapy , Immunotherapy, Adoptive/methods , Indium Radioisotopes , Killer Cells, Natural/diagnostic imaging , Killer Cells, Natural/transplantation , Adult , Aged , Carcinoma, Renal Cell/immunology , Cell Survival , Cell Transplantation/methods , Humans , Kidney Neoplasms/diagnostic imaging , Kidney Neoplasms/immunology , Kidney Neoplasms/therapy , Middle Aged , Organ Specificity , Polymerase Chain Reaction/methods , Radionuclide Imaging , Radiopharmaceuticals , Reproducibility of Results , Sensitivity and Specificity , Tissue Distribution , Transplantation, Homologous/methods
15.
Neurosci Lett ; 354(1): 69-73, 2004 Jan 02.
Article in English | MEDLINE | ID: mdl-14698484

ABSTRACT

Selective attention processes (N2 and P3 components of event-related potentials (ERPs)) have been shown to be impaired in depressed patients but findings have been mixed. Part of this variability might be explained by neurobiological factors. ERPs (Go/Nogo paradigm) were investigated in patients with remitted major depression in relation to S100B. S100B, an astroglial protein with neuroplastic properties, has been shown to be increased in depression. Its pathophysiologic role in depression, however, is not yet sufficiently understood. Patients with increased S100B serum levels (n=6) showed a normal N2- and P3-amplitude in contrast to a reduced N2- and P3-amplitude in patients with normal S100B serum levels (n=6). These findings provide evidence of a correlation between S100B levels and attentional processes in patients with recurrent depression and further substantiate S100B's role as a marker in the course of affective disorders.


Subject(s)
Depressive Disorder, Major/blood , Depressive Disorder, Major/physiopathology , Nerve Growth Factors/blood , S100 Proteins/blood , Attention , Biomarkers , Cognition , Depressive Disorder, Major/diagnosis , Evoked Potentials , Female , Humans , Male , S100 Calcium Binding Protein beta Subunit
16.
Shock ; 20(3): 213-7, 2003 Sep.
Article in English | MEDLINE | ID: mdl-12923491

ABSTRACT

The balance between proinflammatory and anti-inflammatory processes is of key importance in the reaction of the body to infection, injury, and surgical trauma. Drugs commonly used in anesthesia and intensive care may modulate immunological reactions by influencing intercellular communication through modification of cytokine response and fluctuation of peripheral immune cells such as natural killer (NK) cells, B cells, and T lymphocyte subpopulations (CD4+ and CD8+ cells). To examine the effects of general anesthesia with the hypnotic agent propofol and the opioid fentanyl, 30 patients undergoing minor elective orthopedic surgery were studied before and 20 min after application of the anesthetic drugs, but before the start of surgery. We found a significant enhancement of TNF-alpha and IL-1beta release in lipopolysaccharide (LPS)-stimulated whole blood cultures after induction of anesthesia. Similar results were observed with interferon-gamma (IFN-gamma) in cultures stimulated with phytohemagglutinin (PHA). Conversely, synthesis of the anti-inflammatory cytokine interleukin 10 (IL-10) decreased significantly in LPS-stimulated cultures. During general anesthesia, we found a decrease of circulating lymphocytes, characterized by a significant increase in the percentage of T lymphocytes in favor of CD4+ cells, increased B lymphocytes, and a significant decrease of NK cells. These data suggest that anesthesia with propofol and fentanyl promotes proinflammatory immune responses and influences peripheral lymphocyte composition in patients, which may subsequently affect pathophysiological processes during opioid-based anesthesia.


Subject(s)
Analgesics, Opioid/pharmacology , Anesthetics, Intravenous/pharmacology , Lymphocyte Subsets/drug effects , Adolescent , Adult , Anesthesia, General , B-Lymphocytes/metabolism , CD4-Positive T-Lymphocytes/metabolism , Cell Division , Female , Fentanyl/pharmacology , Humans , Interferon-gamma/metabolism , Interferon-gamma/pharmacology , Interleukin-1/blood , Interleukin-10/metabolism , Killer Cells, Natural/metabolism , Lipopolysaccharides/pharmacology , Male , Middle Aged , Phytohemagglutinins/pharmacology , T-Lymphocytes/metabolism , Time Factors , Tumor Necrosis Factor-alpha/biosynthesis
17.
Eur Neuropsychopharmacol ; 13(4): 235-9, 2003 Aug.
Article in English | MEDLINE | ID: mdl-12888182

ABSTRACT

S100B is a protein which exerts both detrimental and neurotrophic effects, depending on its concentration in brain tissue. An increase of S100B in micromolar concentrations is observed in traumatic brain conditions and is associated with poor outcome. Micromolar levels of extracellular S100B in vitro may have deleterious effects. However, in nanomolar concentrations S100B has multiple neurotrophic effects in vitro may in vivo be regarded as a hallmark of neuroprotective efforts. This pilot study addresses the hypothesis that S100B serum concentrations may be of predictive validity for the response to antidepressant treatment in patients with major depression. S100B plasma levels were determined in 25 patients with major depression and 25 matched healthy controls using an immunofluorimetric sandwich assay. S100B plasma levels were significantly higher in major depressive patients than in healthy controls and positively correlated with treatment response after 4 weeks of treatment. In a linear regression model, a significant predictive effect was found only for S100B and severity of depressive symptoms upon admission. These results suggest that neuroprotective functions of S100B counterbalance neurodegenerative mechanisms that are involved in the pathophysiology of major depression and in the response to antidepressant treatment.


Subject(s)
Antidepressive Agents/therapeutic use , Depressive Disorder, Major/drug therapy , Nerve Growth Factors/therapeutic use , S100 Proteins/therapeutic use , Adult , Antidepressive Agents/blood , Case-Control Studies , Depressive Disorder, Major/blood , Diagnostic and Statistical Manual of Mental Disorders , Enzyme-Linked Immunosorbent Assay , Female , Humans , Linear Models , Male , Mental Status Schedule , Middle Aged , Nerve Growth Factors/blood , Pilot Projects , Predictive Value of Tests , Reproducibility of Results , S100 Calcium Binding Protein beta Subunit , S100 Proteins/blood
18.
Transfusion ; 43(7): 893-8, 2003 Jul.
Article in English | MEDLINE | ID: mdl-12823749

ABSTRACT

BACKGROUND: In some situations, the administration of D+ RBCs to D- patients is necessary. The probability of a subsequent anti-D formation is assumed to be around 80 percent, a figure based primarily on studies in healthy volunteers. It was hypothesized that patients requiring blood transfusion have a much lower probability of developing antibodies. STUDY DESIGN AND METHODS: A retrospective analysis was performed whereby 78 D- patients were evaluated for the development of RBC antibodies after administration of D+ RBCs. For the analysis of the cross-sectional observations, parametric models were used for interval-censored data. RESULTS: Anti-D was detected in 16 of 78 patients. Considering the individual patient's inspection times, the calculated probability of developing antibody following D+ RBC supply was shown to be below 41.7 percent (upper 95% confidence bound) and estimated as 30.4 percent. The data hinted toward an inverse correlation between the number of transfused units and the probability of antibody formation. Interestingly, 6 of these 16 patients developed additional IgG autoantibody. In 3 of those cases, evidence for prolonged hemolysis was found. CONCLUSION: The actual frequency of antibody formation in our patients is much lower than assumed. On the other hand, prolonged hemolysis probably induced by additional autoreactive antibodies might occur. This possible complication has not yet been addressed. Further studies might reveal whether a less restricted transfusion policy with respect to D matching is justified in selected patients.


Subject(s)
Blood Group Incompatibility/immunology , Erythrocyte Transfusion , Isoantibodies/blood , Rh-Hr Blood-Group System/immunology , Adult , Aged , Antibody Formation , Autoantibodies/blood , Female , Humans , Male , Middle Aged , Time Factors
19.
J Clin Microbiol ; 41(6): 2428-32, 2003 Jun.
Article in English | MEDLINE | ID: mdl-12791859

ABSTRACT

Marek's disease virus (MDV) causes a common lymphomatous and neuropathic disease in domestic chickens and, less commonly, turkeys and quail. It is a member of the alpha-herpesviruses and until now was considered to be strongly cell associated. In 1991, MDV was suggested to be the causative infectious agent of multiple sclerosis (MS) in humans. In a previous study, we investigated the leukocytes of 107 well-defined MS patients for the presence of MDV DNA but were unable to confirm a role for MDV in the pathogenesis of MS. A recent report (S. Laurent, E. Esnault, G. Dambrine, A. Goudeau, D. Choudat, and D. Rasschaert, J. Gen. Virol. 82:233-240, 2001) described the detection of MDV DNA in 20% of 202 human serum samples, regardless of whether the individuals were exposed to poultry. The detection of MDV DNA in chicken serum samples was reported as well. The aim of the present study was to investigate whether we can confirm the presence of MDV DNA in chickens and humans if we use plasma as the source for nucleic acid isolation. Leukocytes and plasma specimens from 16 chickens experimentally infected with MDV serotype 1 and plasma specimens from 300 volunteer blood donors were tested for MDV DNA by two different TaqMan PCR assays. MDV DNA was repeatedly found in the leukocytes as well as in the plasma specimens of all 16 animals. All human samples analyzed, however, tested negative by both assays. Accordingly, Marek's disease in chickens can be diagnosed by detection of MDV DNA in plasma as well as in leukocytes. Once again, we found no evidence for the spread of MDV to humans.


Subject(s)
Chickens/virology , DNA, Viral/blood , Herpesvirus 2, Gallid/isolation & purification , Marek Disease/virology , Animals , Humans , Marek Disease/transmission , Polymerase Chain Reaction/methods , Poultry Diseases/transmission , Poultry Diseases/virology , Sensitivity and Specificity , Taq Polymerase
20.
Med Microbiol Immunol ; 192(2): 93-7, 2003 May.
Article in English | MEDLINE | ID: mdl-12736822

ABSTRACT

After the recent diphtheria epidemics in Eastern Europe in the early 1990s, we re-evaluated the diphtheria and tetanus immunity of 321 German blood donors (192 men and 129 women). The mean antitoxin levels of all blood donors in this study, measured by commercial ELISA, revealed a questionable protection (0.1-1.0 IU/ml) against diphtheria. In 1994, 66.4% were without immunity against diphtheria (55.0% in 1997/98), 32.1% (41.5% in 1997/98) showed questionable protection and only 1.5% (3.5% in 1997/98) had protective antitoxin levels. The evaluation of tetanus immunity revealed only 0.5% (1.1% in 1997/98) of the subjects with no protection and 9.1% (8.5% in 1997/98) with questionable protection. For this reason, we conclude that the diphtheria epidemics only lead to an insufficient improvement of the immunization status in a healthy German population.


Subject(s)
Blood Donors , Diphtheria/immunology , Tetanus/immunology , Adolescent , Adult , Aged , Blood Donors/statistics & numerical data , Diphtheria/epidemiology , Diphtheria/prevention & control , Diphtheria Antitoxin/analysis , Diphtheria Antitoxin/blood , Diphtheria Toxoid/administration & dosage , Diphtheria Toxoid/immunology , Enzyme-Linked Immunosorbent Assay , Female , Germany/epidemiology , Humans , Immunization , Immunoglobulin G/analysis , Male , Middle Aged , Seroepidemiologic Studies , Surveys and Questionnaires , Tetanus/epidemiology , Tetanus/prevention & control , Tetanus Antitoxin/analysis , Tetanus Antitoxin/blood , Tetanus Toxoid/administration & dosage , Tetanus Toxoid/immunology
SELECTION OF CITATIONS
SEARCH DETAIL
...